Business context and reporting period
The supplied filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023; this differs from the requested company name, Chronoscale Holdings Corp. Ekso designs and sells medical and industrial exoskeletons. Its EksoHealth business includes EksoNR and products acquired with the Human Motion and Control (HMC) business in December 2022; EksoWorks focuses on industrial devices.
Key financial metrics
Unless otherwise noted, amounts are in U.S. dollars and millions.
| Metric | Q1 2023 | Q1 2022 / prior balance |
|---|---|---|
| Revenue | $4.12 | $2.57 |
| Gross profit / margin | $2.00 / 49% | $1.21 / 47% |
| Operating expenses | $6.45 | $5.45 |
| Operating loss | $(4.45) | $(4.24) |
| Net loss | $(4.39); $(0.33) per share | $(4.62); $(0.36) per share |
| Cash used in operations | $(4.21) | $(4.21) |
| Cash and cash equivalents, quarter-end | $16.28 | $20.53 at Dec. 31, 2022 |
| Working capital | $18.1 | $21.8 at Dec. 31, 2022 |
Cash was approximately $14.28 million after the $2.0 million required under the bank-loan liquidity covenant. Total liabilities were $15.82 million and stockholders’ equity was $21.28 million at quarter-end. Notes payable had a reported carrying value of approximately $6.16 million: a $2.0 million bank term loan due August 2023 and the discounted Parker acquisition note. The Parker note has $5.0 million of scheduled principal payments, beginning in December 2023.
Material changes versus the prior comparable period
- Revenue rose 61% year over year, primarily on higher EksoHealth sales, including increased EksoNR unit volume. The company booked 23 EksoNR units in Q1 2023.
- EksoHealth revenue increased about $2.1 million; EksoWorks revenue declined about $0.6 million, reflecting lower EVO and EksoVest sales and the absence of prior-year prepaid royalty revenue.
- Gross margin improved to 49% from 47%, principally due to lower device costs. Operating expenses increased 18%, including HMC-related headcount, marketing, development, audit and integration costs.
- Net loss narrowed by $0.23 million, although operating loss increased. Other income improved, including a $0.22 million unrealized foreign-exchange gain versus a $0.25 million loss in Q1 2022.
- Cash fell $4.25 million from year-end. Operating cash use was approximately flat year over year; investing cash use was $0.04 million.
Outlook, risks and unusual items
- Going concern and funding: The company reports expected future operating losses and negative operating cash flows, and says additional funding will be needed. Management states cash on hand is sufficient to finance operations until Q1 2024 and believes expense reductions are probable and will alleviate substantial doubt for at least 12 months from issuance. Financing plans are not assured; management identifies possible equity offerings, ATM sales, debt or receivables factoring.
- Debt and liquidity: The $2.0 million Pacific Western Bank term loan matures in August 2023. The company must maintain cash equal to the outstanding loan balance under its liquidity covenant. It also has $3.8 million in purchase obligations expected within one year and $1.48 million in operating lease payments over the lease terms.
- Operating risks: Management cites supply shortages, longer lead times and higher input costs; hospital financial pressures and reduced capital spending; lengthy sales cycles; competition, regulatory and reimbursement uncertainties; and foreign-currency exposure. The company says it may stockpile components, which could increase inventory and near-term cash use.
- Acquisition and contingencies: HMC purchase-price allocations remain preliminary. A related-party settlement provides for $0.325 million in cash payments; $0.18 million remained payable at March 31. Management says ordinary-course legal matters are not expected to have a material adverse effect. The company ceased commercialization of EksoZeroG in 2022.
- No quantitative revenue or earnings guidance is provided. The filing says Q1 results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Confirm the filing entity: the supplied 10-Q is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp.
- Track funding availability, cash burn, and repayment or refinancing of the August 2023 bank loan against management’s stated runway.
- Monitor EksoHealth sales growth and whether it offsets continued weakness in EksoWorks.
- Review final HMC acquisition fair values, integration costs, and the effect of acquisition-note payments.
- Assess customer concentration: two customers represented 26% and 14% of Q1 revenue, and one customer represented 30% of quarter-end receivables.